Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study

BACKGROUND: While docetaxel/cisplatin/5‐fluorouracil (DCF) outperforms CF in first‐line gastric adenocarcinoma, toxicity remains an issue. METHODS: This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/m(2), C 35 mg/m², F...

Descripción completa

Detalles Bibliográficos
Autores principales: Deleporte, Amélie, Van den Eynde, Marc, Forget, Frédéric, Holbrechts, Stéphane, Delaunoit, Thierry, Houbiers, Ghislain, Kalantari, Hassan R., Laurent, Stéphanie, Vanderstraeten, Erik, De Man, Marc, Vergauwe, Philippe, Clausse, Marylene, Van Der Auwera, Jacques, D’Hondt, Lionel, Pierre, Pascal, Ghillemijn, Bjorn, Covas, Angelique, Paesmans, Marianne, Ameye, Lieveke, Awada, Ahmad, Sclafani, Francesco, Hendlisz, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267119/
https://www.ncbi.nlm.nih.gov/pubmed/34057299
http://dx.doi.org/10.1002/cam4.3976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267119/
https://www.ncbi.nlm.nih.gov/pubmed/34057299
http://dx.doi.org/10.1002/cam4.3976

Ejemplares similares